TCG Crossover Management’s Dyne Therapeutics DYN Stock Holding History

TCG Crossover Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$83.7M	Hold	4,615,144	–	–	2.39%	15
2025 Q4	$90.3M	Hold	4,615,144	–	–	2.99%	6
2025 Q3	$58.4M	Buy	4,615,144 +848,484	+23%	+$9.68M	2.87%	10
2025 Q2	$35.9M	Buy	3,766,660 +1,116,510	+42%	+$12.3M	4.1%	10
2025 Q1	$27.7M	Hold	2,650,150	–	–	3.78%	8
2024 Q4	$62.4M	Hold	2,650,150	–	–	6.1%	2
2024 Q3	$95.2M	Hold	2,650,150	–	–	8.07%	2
2024 Q2	$93.5M	Hold	2,650,150	–	–	9.75%	2
2024 Q1	$75.2M	Buy	2,650,150 +1,000,000	+61%	+$22.6M	5.95%	2
2023 Q4	$21.9M	Hold	1,650,150	–	–	2.43%	18
2023 Q3	$14.8M	Hold	1,650,150	–	–	2.18%	18
2023 Q2	$18.6M	Hold	1,650,150	–	–	3.04%	11
2023 Q1	$19M	Buy	+1,650,150	New	+$21.4M	3.71%	11

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

TCG Crossover Management's DYN Position: Q1 2026 in Review

TCG Crossover Management held its Dyne Therapeutics (DYN) position steady in Q1 2026 at 4,615,144 shares worth $83.7M. The position accounts for 2.39% of the portfolio, ranked #15.

TCG Crossover Management first reported a position in DYN in Q1 2023 and has held it in 13 quarters since. The position peaked at $95.2M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

TCG Crossover Management held 4,615,144 shares of Dyne Therapeutics worth $83.7M as of Q1 2026.
TCG Crossover Management left its Dyne Therapeutics share count unchanged in Q1 2026.
Dyne Therapeutics made up 2.39% of TCG Crossover Management's portfolio in Q1 2026, its #15 holding.
TCG Crossover Management first reported a position in Dyne Therapeutics in Q1 2023 and has held it in 13 quarters since.
TCG Crossover Management's Dyne Therapeutics position peaked at $95.2M in Q3 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.